PMID- 38022413
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 1011-6842 (Print)
IS  - 1011-6842 (Linking)
VI  - 39
IP  - 6
DP  - 2023 Nov
TI  - Galectin-3 as a Biomarker to Predict Cardiorenal Syndrome in Patients with Acute 
      Heart Failure.
PG  - 862-870
LID - 10.6515/ACS.202311_39(6).20230903A [doi]
AB  - BACKGROUND: Galectin-3 affects cardiac tissue inflammation as an inflammatory 
      mediator. The development of cardiorenal syndrome in heart failure patients is 
      associated with a poor prognosis. This study aims to investigate whether serum 
      galectin-3 levels can be used as a biomarker to predict cardiorenal syndrome in 
      heart failure patients with reduced left ventricular ejection fraction. METHODS: 
      A total of 166 symptomatic heart failure patients [New York Heart Association 
      (NYHA) functional class II-III] with reduced left ventricular ejection fraction 
      (</= 40%) were recruited prospectively. Cardiorenal syndrome type 1 was defined as 
      an acute worsening of cardiac function leading to renal dysfunction. The patients 
      were divided into two groups with and without cardiorenal syndrome. The 
      galectin-3 levels of all patients were determined. The primary outcome of this 
      study was the occurrence of cardiorenal syndrome. RESULTS: Cardiorenal syndrome 
      developed in 41 patients. Galectin-3 levels were found to be higher in the 
      patients with cardiorenal syndrome (+) compared to those without cardiorenal 
      syndrome (-) (20.7 +/- 2.9 ng/mL vs. 17.8 +/- 3.1 ng/mL, p < 0.001). After performing 
      a multivariable analysis, galectin-3 levels [odds ratio (OR): 3.21, p = 0.001], 
      NYHA functional class (OR: 1.98, p = 0.009), creatinine (OR: 3.18, p = 0.006), 
      furosemide dose (OR: 1.21, p = 0.033), and angiotensin-converting enzyme 
      inhibitor/angiotensin-receptor blockers usage (OR: 0.54, p = 0.029) were 
      identified as independent predictors for the development of cardiorenal syndrome. 
      Moreover, galectin-3 level demonstrated predictive capability for cardiorenal 
      syndrome development (AUC = 0.761, p < 0.001). CONCLUSIONS: Serum galectin-3 
      level showed an association with cardiorenal syndrome development in patients 
      with heart failure, indicating potential usefulness as a prognostic biomarker.
FAU - Ozyildirim, Serhan
AU  - Ozyildirim S
AD  - Institute of Cardiology, Department of Cardiology, Istanbul University- 
      Cerrahpasa.
FAU - Dogan, Omer
AU  - Dogan O
AD  - Department of Cardiology, Ministry of Health, Istinye State Hospital.
FAU - Barman, Hasan Ali
AU  - Barman HA
AD  - Institute of Cardiology, Department of Cardiology, Istanbul University- 
      Cerrahpasa.
FAU - Tanyolac, Selim
AU  - Tanyolac S
AD  - Institute of Cardiology, Department of Cardiology, Istanbul University- 
      Cerrahpasa.
FAU - Atici, Adem
AU  - Atici A
AD  - Istanbul Medeniyet University, Faculty of Medicine, Department of Cardiology, 
      Goztepe Training and Research Hospital, Istanbul, Turkey.
FAU - Enar, Rasim
AU  - Enar R
AD  - Institute of Cardiology, Department of Cardiology, Istanbul University- 
      Cerrahpasa.
FAU - Dogan, Sait Mesut
AU  - Dogan SM
AD  - Institute of Cardiology, Department of Cardiology, Istanbul University- 
      Cerrahpasa.
LA  - eng
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Acta Cardiol Sin
JT  - Acta Cardiologica Sinica
JID - 101687085
PMC - PMC10646596
OTO - NOTNLM
OT  - Cardiorenal syndrome
OT  - Galectin-3
OT  - Heart failure
COIS- All the authors declare no conflict of interest.
EDAT- 2023/11/29 18:41
MHDA- 2023/11/29 18:42
PMCR- 2023/11/01
CRDT- 2023/11/29 15:23
PHST- 2023/01/27 00:00 [received]
PHST- 2023/09/03 00:00 [accepted]
PHST- 2023/11/29 18:42 [medline]
PHST- 2023/11/29 18:41 [pubmed]
PHST- 2023/11/29 15:23 [entrez]
PHST- 2023/11/01 00:00 [pmc-release]
AID - 10.6515/ACS.202311_39(6).20230903A [doi]
PST - ppublish
SO  - Acta Cardiol Sin. 2023 Nov;39(6):862-870. doi: 
      10.6515/ACS.202311_39(6).20230903A.